ERBB2 and neoplasm: It is defined by ASCO/CAP (2013) guidelines as the presence of ≥10% to <50% tumour cells with a ratio ≥ 2.0 when using dual probes or ≥6 HER2 signals/cell when using single probes, selecting 2–4 representative invasive tumour areas [16].